Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2598 of 3330
Next
>>
>
64926 to 64950 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
ZR75B	HR+	Luminal	SB-3CT	MMP2/9	MMP	100	uM	11939.144	0.5161	0.3378	1.6446
184A1	NM	Basal	Selumetinib	MEK	MAPK	0.000128	uM	12509.155	1.0871	1.1281	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	0.00064	uM	12509.155	1.0345	1.0511	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	0.0032	uM	12509.155	1.0219	1.0325	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	0.016	uM	12509.155	0.9578	0.9368	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	0.08	uM	12509.155	0.8466	0.7670	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	0.4	uM	12509.155	0.6790	0.4996	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	2	uM	12509.155	0.4617	0.1255	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	10	uM	12509.155	0.4163	0.0422	1.3444
184A1	NM	Basal	Selumetinib	MEK	MAPK	50	uM	12509.155	0.4208	0.0504	1.3444
184B5	NM	Basal	Selumetinib	MEK	MAPK	0.000128	uM	12566.155	1.0180	1.0234	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	0.00064	uM	12566.155	0.9704	0.9613	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	0.0032	uM	12566.155	0.9304	0.9084	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	0.016	uM	12566.155	0.8646	0.8195	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	0.08	uM	12566.155	0.6887	0.5695	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	0.4	uM	12566.155	0.5831	0.4086	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	2	uM	12566.155	0.4144	0.1282	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	10	uM	12566.155	0.3767	0.0605	1.5389
184B5	NM	Basal	Selumetinib	MEK	MAPK	50	uM	12566.155	0.4222	0.1420	1.5389
600MPE	HR+	Luminal	Selumetinib	MEK	MAPK	0.000128	uM	12224.155	0.9984	0.9969	1.0378
600MPE	HR+	Luminal	Selumetinib	MEK	MAPK	0.00064	uM	12224.155	0.9670	0.9363	1.0378
600MPE	HR+	Luminal	Selumetinib	MEK	MAPK	0.0032	uM	12224.155	0.9944	0.9892	1.0378
600MPE	HR+	Luminal	Selumetinib	MEK	MAPK	0.016	uM	12224.155	0.8938	0.7949	1.0378
600MPE	HR+	Luminal	Selumetinib	MEK	MAPK	0.08	uM	12224.155	0.7998	0.6128	1.0378
600MPE	HR+	Luminal	Selumetinib	MEK	MAPK	0.4	uM	12224.155	0.7906	0.5948	1.0378

|<
<<
Previous
Page 2598 of 3330
Next
>>
>
64926 to 64950 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)